It seems that blocking the activity of TLR9 in a course of anticancer therapy can achieve two purposes: (1) reduce the resistance of cancer cells to treatment and (2) promote cell death due to activation of AIM2-associated signaling pathway. The gene discussed is TLR9; the disease is cancer.